Market Overview

Sunshine Biopharma Launches Microbiology Testing Service

Share:

MONTREAL, QC / ACCESSWIRE / June 18, 2018 / Sunshine Biopharma, Inc. (OTC PINK: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of cancer, today announced that it has purchased all of the necessary equipment for Microbiology Testing Service and will be launching the service through its wholly owned subsidiary, Atlas Pharma Inc. Presently, Atlas Pharma offers analytical chemistry testing.

"This is in line with our stated plans to expand the operations of Atlas. Microbiology Testing is one of the most frequently requested analytical tests for most industrial samples," said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. "We are pleased to be adding this new milestone in the growth of our firm," he added.

About Atlas Pharma

Atlas Pharma Inc. was founded in 2012 and acquired by Sunshine Biopharma in January 2018. The company offers analytical chemistry testing services to the pharmaceutical, cosmetic and natural products industry. Atlas has 9 full-time employees and operates in a 5,250 square foot facility located in Montreal (Canada). Atlas Pharma operations are authorized by a Drug Establishment License (DEL) issued by Health Canada and are fully compliant with the requirements of Good Manufacturing Practices (GMP). Atlas Pharma is also registered with the FDA. More information about Atlas Pharma is available at www.atlaspharmainc.ca.

About Sunshine Biopharma

Sunshine Biopharma is pharmaceutical company operating in the pharmaceutical testing services sector, as well as, in the research, development and commercialization of drugs for the treatment of cancer. Sunshine Biopharma's business plan includes the clinical development of Adva-27a, the Company's proprietary anticancer compound. Tests conducted on Adva-27a have demonstrated the drug's effectiveness at destroying Multidrug Resistant Cancer Cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada.

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information Contact:

Camille Sebaaly, CFO Sunshine Biopharma Inc.

Direct Line: 514-814-0464

camille.sebaaly@sunshinebiopharma.com

www.sunshinebiopharma.com

SOURCE: Sunshine Biopharma Inc.

View Comments and Join the Discussion!